Cells expressing modified T cell receptor
View Patent ↗This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs.
1. A method for obtaining modified mammalian cell, wherein the modified mammalian cell comprising a membrane presenting at least one modified T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, the modified TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs, which method comprises incubating mammalian cell containing an expression vector encoding the modified TCR under conditions whereby the modified TCR is expressed, thereby obtaining the modified mammalian cell.
2. A method of directing immune cells to a population of target cells in a patient, said method comprising administering to the patient a plurality of immune cells comprising a membrane presenting at least one modified TCR anchored to the membrane by a transmembrane sequence, wherein the modified TCR comprises an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs wherein the modified TCR presented by such cells is specific for a TCR ligand presented on the target cells thereby directing the cells to the population of target cells in the patient.
3. A method of directing a T cell response to a target cell in a patient, said method comprising administering to the patient a plurality of T cells comprising a membrane presenting at least one modified TCR anchored to the membrane by a transmembrane sequence, wherein the modified TCR comprises an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs, wherein the modified TCR presented by such T cells is specific for a TCR ligand presented on the target cell, thereby directing the T cell response to the target cell in the patient.
4. The method according to claim 2 wherein the TCR ligand presented on the target cells is a peptide-MHC complex or a CD1-antigen complex.
5. The method according to claim 2 wherein the administered cells are not cytotoxic T cells.
6. The method according to claim 2 wherein the target cell is a cancer cell or infected cell and the administered cells are cytotoxic T cells.
7. The method according to claim 2 wherein the TCR ligand is unique to one tissue type or to cells characteristic of one organ of the body.
8. The method according to claim 7 wherein the target cell is a target for autoreactive T cells in autoimmune disease, organ rejection or graft versus host disease (GVHD).
9. The method according to claim 8 wherein the target cell is an islet cell.
10. A method for the preparation of cells comprising a membrane presenting a plurality of modified (TCRs) anchored to the membrane by a transmembrane sequence, wherein the modified TCRs comprise an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs, said method comprising: (a) isolation of a population of cells (b) in vitro transfection of said population of cells with an expression vector encoding the modified TCRs, said TCRs being specific for a target cell, and optionally (c) in vitro growth of the transfected cells.
11. The method according to claim 10 wherein the cells are T cells.
12. The method according to claim 10 wherein the population of cells is isolated from a patient who is to be treated by directing immune cells comprising a membrane presenting at least one modified TCR anchored to the membrane by a transmembrane sequence, wherein the modified TCR comprises an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs wherein the modified TCR presented by such cells is specific for a TCR ligand on the population of target cells to a population of target cells in the patient.
13. A method of treatment of cancer, GVHD, infection, organ rejection, or autoimmune disease comprising administering a plurality of immune cells comprising a membrane presenting at least one modified TCR anchored to the membrane by a transmembrane sequence, wherein the modified TCR comprises an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs.
14. The method according to claim 13 wherein the auto-immune disease is rheumatoid arthritis, diabetes, multiple sclerosis or reactive arthritis.
15. The method according to claim 3 wherein the TCR ligand on the target cell type is a peptide-MHC complex or a CD1-antigen complex.
16. The method according to claim 3 wherein the administered cells are not cytotoxic T cells.
17. The method according to claim 3 wherein the target cell is a cancer cell or infected cell and the administered cells are cytotoxic T cells.
18. The method according to claim 3 wherein the TCR ligand is unique to one tissue type or to cells characteristic of one organ of the body.
19. The method according to claim 18 wherein the target cell is a target for autoreactive T cells in autoimmune disease, organ rejection or (GVHD).
20. The method according to claim 19 wherein the target cell is an islet cell.